Annals of Oncology Advance Access originally published online on September 6, 2007
Annals of Oncology 2008 19(1):123-127; doi:10.1093/annonc/mdm437
lung cancer |
Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study
1 Division of Oncology, Department of Internal medicine, Asan Medical Center, Seoul
2 Department of Hematology & Oncology, Chung-Ang University Medical Center, Seoul
3 Department of Hemato-oncoloogy, Korea Cancer Center Hospital, Seoul
4 Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Seoul
5 Department of Oncology and Hematology, Korea University Medical Center, Seoul
6 Division of Hematology/Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
* Correspondence to: Dr J.-S. Lee, Division of Oncology, Department of Internal Medicine, University of Ulsan, College of Medicine, Asan Medical Center, 388-1 Pungnap-2 dong, Songpa-gu, Seoul 138-736, Korea. Tel: +82-2-3010-3212; Fax: +82-2-3010-6961; E-mail: jayslee{at}amc.seoul.kr
Background: Belotecan (Camtobell®, Chong Keun Dang Corp, Seoul, Korea; CKD602) is a new camptothecin analogue. This study aimed to investigate the safety and efficacy of single-agent belotecan for small-cell lung cancer (SCLC).
Patients and methods: Twenty-seven patients with chemotherapy-naive or chemosensitive SCLC were treated with belotecan 0.5 mg/m2/day on days 1–5 of a 3-week cycle. All 27 patients were assessable for toxicity, and 21 patients assessable for response.
Results: Nine patients (42.9%) showed objective tumor responses including one complete response; seven (63.6%) in 11 chemotherapy-naive patients; and two (20.0%) in 10 chemosensitive patients. With a median follow-up of 5 years, median progression-free and survival time for chemotherapy-naive patients were 4.8 months and 11.9 months, respectively, while the corresponding values for chemosensitive patients were 3.3 months and 10.5 months, respectively. The most common toxicity was neutropenia.
Conclusion: Belotecan was active in SCLC patients as a single agent, warranting further investigations of belotecan in combination with platinum or other active agents.
Key words: belotecan, single agent, small-cell lung cancer
Received for publication June 12, 2007. Revision received July 28, 2007. Accepted for publication August 2, 2007.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  I. K. Demedts, K. Y. Vermaelen, and J. P. van Meerbeeck Treatment of extensive-stage small cell lung carcinoma: current status and future prospects Eur. Respir. J., January 1, 2010; 35(1): 202 - 215. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Zamboni, S. Ramalingam, D. M. Friedland, R. P. Edwards, R. G. Stoller, S. Strychor, L. Maruca, B. A. Zamboni, C. P. Belani, and R. K. Ramanathan Phase I and Pharmacokinetic Study of Pegylated Liposomal CKD-602 in Patients with Advanced Malignancies Clin. Cancer Res., February 15, 2009; 15(4): 1466 - 1472. [Abstract] [Full Text] [PDF]
|
|